Turnstone Biologics (TSBX) Competitors $0.47 +0.01 (+2.54%) (As of 11:01 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TSBX vs. ATNM, ACHL, OMGA, GANX, RLYB, VYNE, DYAI, RVPH, CERO, and CVMShould you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Actinium Pharmaceuticals (ATNM), Achilles Therapeutics (ACHL), Omega Therapeutics (OMGA), Gain Therapeutics (GANX), Rallybio (RLYB), VYNE Therapeutics (VYNE), Dyadic International (DYAI), Reviva Pharmaceuticals (RVPH), CERo Therapeutics (CERO), and CEL-SCI (CVM). These companies are all part of the "pharmaceutical products" industry. Turnstone Biologics vs. Actinium Pharmaceuticals Achilles Therapeutics Omega Therapeutics Gain Therapeutics Rallybio VYNE Therapeutics Dyadic International Reviva Pharmaceuticals CERo Therapeutics CEL-SCI Turnstone Biologics (NASDAQ:TSBX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment. Which has more risk and volatility, TSBX or ATNM? Turnstone Biologics has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Is TSBX or ATNM more profitable? Actinium Pharmaceuticals' return on equity of -100.85% beat Turnstone Biologics' return on equity.Company Net Margins Return on Equity Return on Assets Turnstone BiologicsN/A -105.99% -87.27% Actinium Pharmaceuticals N/A -100.85%-47.89% Does the media prefer TSBX or ATNM? In the previous week, Actinium Pharmaceuticals had 6 more articles in the media than Turnstone Biologics. MarketBeat recorded 11 mentions for Actinium Pharmaceuticals and 5 mentions for Turnstone Biologics. Actinium Pharmaceuticals' average media sentiment score of -0.14 beat Turnstone Biologics' score of -0.40 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turnstone Biologics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in TSBX or ATNM? Actinium Pharmaceuticals received 1 more outperform votes than Turnstone Biologics when rated by MarketBeat users. However, 50.00% of users gave Turnstone Biologics an outperform vote while only 38.46% of users gave Actinium Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTurnstone BiologicsOutperform Votes450.00% Underperform Votes450.00% Actinium PharmaceuticalsOutperform Votes538.46% Underperform Votes861.54% Do institutionals & insiders have more ownership in TSBX or ATNM? 52.5% of Turnstone Biologics shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 32.1% of Turnstone Biologics shares are held by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer TSBX or ATNM? Turnstone Biologics currently has a consensus target price of $2.13, suggesting a potential upside of 350.59%. Actinium Pharmaceuticals has a consensus target price of $7.40, suggesting a potential upside of 432.37%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Turnstone Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turnstone Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has stronger valuation and earnings, TSBX or ATNM? Actinium Pharmaceuticals has lower revenue, but higher earnings than Turnstone Biologics. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTurnstone Biologics$19.31M0.56-$55.20M-$3.24-0.15Actinium Pharmaceuticals$80K542.10-$48.82M-$1.39-1.00 SummaryActinium Pharmaceuticals beats Turnstone Biologics on 11 of the 17 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Turnstone Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSBX vs. The Competition Export to ExcelMetricTurnstone BiologicsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.91M$2.95B$5.08B$8.80BDividend YieldN/A1.91%5.02%4.07%P/E Ratio-0.1517.5291.2813.60Price / Sales0.56280.411,226.2187.40Price / CashN/A169.3839.4536.27Price / Book0.254.366.906.33Net Income-$55.20M-$41.63M$118.83M$225.93M7 Day Performance-10.66%-5.54%-1.92%-0.96%1 Month Performance-10.68%-7.28%-3.75%1.06%1 Year Performance-80.75%25.27%31.37%26.59% Turnstone Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSBXTurnstone Biologics3.2023 of 5 stars$0.47+2.5%$2.13+350.6%-84.8%$10.91M$19.31M-0.1582ATNMActinium Pharmaceuticals1.3027 of 5 stars$1.39flat$7.40+432.4%N/A$43.37M$80,000.000.0049Analyst ForecastACHLAchilles Therapeutics2.8001 of 5 stars$1.05-1.9%$4.00+281.0%+32.1%$43.16MN/A0.00250OMGAOmega Therapeutics1.479 of 5 stars$0.77-2.1%$9.20+1,089.4%-60.5%$42.83M$3.09M-0.59120GANXGain Therapeutics2.5051 of 5 stars$1.61-3.0%$7.33+355.5%-39.0%$42.70M$50,000.000.0020News CoverageGap DownRLYBRallybio2.5309 of 5 stars$1.02+2.6%$9.75+855.9%-59.4%$42.32MN/A0.0040VYNEVYNE Therapeutics2.55 of 5 stars$2.85+1.1%$6.88+141.2%-28.6%$42.04M$420,000.000.0030Analyst ForecastDYAIDyadic International2.1296 of 5 stars$1.40-6.0%$6.00+328.6%-17.7%$41.43M$2.90M-5.657Analyst RevisionRVPHReviva Pharmaceuticals2.6308 of 5 stars$1.21-0.8%$15.50+1,186.3%-71.1%$40.30MN/A0.005CEROCERo TherapeuticsN/A$0.27+6.9%N/AN/A$39.98MN/A0.008Gap DownCVMCEL-SCIN/A$0.60-4.7%N/A-74.0%$38.17MN/A0.0043Analyst Downgrade Related Companies and Tools Related Companies Actinium Pharmaceuticals Competitors Achilles Therapeutics Competitors Omega Therapeutics Competitors Gain Therapeutics Competitors Rallybio Competitors VYNE Therapeutics Competitors Dyadic International Competitors Reviva Pharmaceuticals Competitors CERo Therapeutics Competitors CEL-SCI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TSBX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
